Empaglimet 12.5/500mg Tablet

Empaglimet 12.5/500mg Tablet is a combination medication containing two active ingredients: empagliflozin & metformin hydrochloride (HCl). Empagliflozin belongs to a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors, while metformin is a biguanide antidiabetic agent. This combination tablet is prescribed to help control blood sugar levels in adults with type 2 diabetes mellitus.

Ingredients:

• Empagliflozin
• Metformin Hydrochloride (HCl)

Uses:

• Blood Sugar Control: Empaglimet 12.5/500mg Tablet is used to improve glycemic control in adults with type 2 diabetes by lowering blood sugar levels.
• Diabetes Management: This medication helps to reduce blood glucose levels by increasing urinary glucose excretion (via empagliflozin) and decreasing hepatic glucose production and intestinal glucose absorption (via metformin).
• Cardiovascular Health: In addition to lowering blood sugar levels, empagliflozin has been shown to reduce the risk of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

Dosage:

• The dosage of Empaglimet 12.5/500mg Tablet should be determined by a healthcare professional based on individual patient factors, including blood glucose levels and renal function.
• It is usually taken orally, once or twice daily, with meals.
• The dosage may be adjusted over time to achieve optimal blood sugar control.

Precautions:

• Kidney Function: Patients should have their kidney function assessed before starting treatment with Empaglimet 12.5/500mg Tablet, as both empagliflozin and metformin are excreted primarily by the kidneys.
• Hypoglycemia: Hypoglycemia (low blood sugar) may occur when empagliflozin is used in combination with other antidiabetic medications that can cause hypoglycemia. Patients should be monitored for signs of hypoglycemia, especially when using insulin or insulin secretagogues.
• Lactic Acidosis: Metformin, one of the components of Empaglimet, may increase the risk of lactic acidosis, a serious metabolic complication. This risk is higher in patients with impaired kidney function, liver disease, or conditions associated with hypoxia.
• Pregnancy and Breastfeeding: Empaglimet 12.5/500mg Tablet is not recommended during pregnancy or breastfeeding. Consultation with a healthcare provider is advised.
• Drug Interactions: Patients should inform their healthcare provider about all medications they are taking, as certain drugs may interact with empagliflozin or metformin.

Storage:

• Store Empaglimet 12.5/500mg Tablet at room temperature, away from moisture and heat.
• Keep it out of reach of children and pets.
• Do not use the medication if it has expired or if the packaging is damaged.